US Stock MarketDetailed Quotes
KALV KalVista Pharmaceuticals
- 12.000
- -0.180-1.48%
Trading May 2 15:31 ET
506.26MMarket Cap-3846P/E (TTM)
12.300High11.775Low441.48KVolume12.230Open12.180Pre Close5.30MTurnover1.83%Turnover RatioLossP/E (Static)42.19MShares16.88052wk High5.71P/B289.40MFloat Cap7.21052wk Low--Dividend TTM24.12MShs Float129.108Historical High--Div YieldTTM4.31%Amplitude4.120Historical Low12.001Avg Price1Lot Size
KalVista Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | (Q3)Jan 31, 2023 | (Q2)Oct 31, 2022 | (Q1)Jul 31, 2022 | (FY)Apr 30, 2022 | (Q4)Apr 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -196.81%-27.57M | 3.73%-19.83M | -17.54%-26.73M | 3.68%-75.26M | 15.50%-22.64M | 33.96%-9.29M | -5.37%-20.59M | -28.23%-22.74M | -158.97%-78.13M | -142.54%-26.79M |
| Net income from continuing operations | -36.26%-29.03M | -24.23%-27.65M | -9.87%-25.32M | -12.83%-92.91M | -9.09%-26.31M | 5.19%-21.3M | -13.27%-22.26M | -43.04%-23.04M | -78.05%-82.34M | -61.23%-24.11M |
| Operating gains losses | 27.45%-436K | 155.75%611K | -260.41%-709K | -169.34%-1.48M | -119.67%-224K | -198.85%-601K | -414.04%-1.1M | 1,094.59%442K | 393.40%2.13M | 1,311.70%1.14M |
| Depreciation and amortization | 4.02%207K | 13.87%197K | 22.15%193K | 27.30%718K | 20.51%188K | 33.56%199K | 36.22%173K | 19.70%158K | 5.03%564K | 11.43%156K |
| Other non cash items | -80.00%2K | -200.00%-19K | -73.91%6K | -53.07%84K | 23.08%32K | -90.65%10K | -20.83%19K | 4.55%23K | 57.02%179K | -70.79%26K |
| Change In working capital | -110.47%-1.03M | 1,784.96%3.81M | -25.72%-4.22M | 160.16%7.41M | 115.89%1.13M | 140.22%9.86M | 94.24%-226K | 37.45%-3.36M | -247.64%-12.32M | -6,827.18%-7.14M |
| -Change in receivables | -122.93%-2.11M | 43.23%-2.03M | 41.62%-2.08M | 55.47%-2.32M | -17.21%-4.37M | 59.06%9.19M | 11.73%-3.57M | -11.18%-3.57M | -169.75%-5.2M | -39.06%-3.72M |
| -Change in prepaid assets | -81.65%145K | 2.86%1.76M | -151.83%-1M | 172.09%6.69M | 140.03%2.25M | 163.71%790K | 195.60%1.72M | 409.60%1.94M | -3,703.28%-9.28M | -1,914.70%-5.62M |
| -Change in payables and accrued expense | 907.83%929K | 150.25%4.07M | 34.22%-1.13M | 40.76%3.04M | 47.01%3.25M | 73.26%-115K | -14.78%1.63M | -12.56%-1.72M | 90.56%2.16M | -22.56%2.21M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -196.81%-27.57M | 3.73%-19.83M | -17.54%-26.73M | 3.68%-75.26M | 15.50%-22.64M | 33.96%-9.29M | -5.37%-20.59M | -28.23%-22.74M | -158.97%-78.13M | -142.54%-26.79M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -166.27%-6.7M | 42.08%28.56M | -34.72%19.61M | -28.42%41.42M | -149.94%-6.21M | -119.51%-2.52M | 13.91%20.1M | 101.90%30.04M | 139.19%57.86M | 107.47%12.43M |
| Net PPE purchase and sale | -26.67%-19K | 98.96%-2K | 99.35%-6K | -28.46%-1.2M | 19.77%-69K | 92.57%-15K | 46.07%-192K | -220.56%-920K | -1,035.37%-931K | -160.61%-86K |
| Net intangibles purchase and sale | ---91K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | -163.47%-6.59M | 41.75%28.76M | -36.64%19.62M | -27.52%42.61M | -149.05%-6.14M | -119.09%-2.5M | 12.73%20.29M | 104.14%30.96M | 139.84%58.79M | 107.52%12.52M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -166.27%-6.7M | 42.08%28.56M | -34.72%19.61M | -28.42%41.42M | -149.94%-6.21M | -119.51%-2.52M | 13.91%20.1M | 101.90%30.04M | 139.19%57.86M | 107.47%12.43M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -99.51%284K | -23.81%128K | 21.43%204K | 3,575.90%58.12M | -123.91%-33K | 7,388.73%57.81M | 166.67%168K | -72.37%168K | -99.25%1.58M | -99.93%138K |
| Net common stock issuance | ---- | ---- | ---- | --56.58M | --0 | ---- | ---- | ---- | --0 | --0 |
| Proceeds from stock option exercised by employees | -76.93%284K | -23.81%128K | 21.43%204K | -2.97%1.53M | -123.91%-33K | 59.46%1.23M | 166.67%168K | -72.37%168K | 3.00%1.58M | -89.96%138K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -99.51%284K | -23.81%128K | 21.43%204K | 3,575.90%58.12M | -123.91%-33K | 7,388.73%57.81M | 166.67%168K | -72.37%168K | -99.25%1.58M | -99.93%138K |
| Net cash flow | ||||||||||
| Beginning cash position | 49.45%57.67M | 30.49%49.41M | 82.99%56.24M | -39.26%30.73M | 86.61%85.05M | -17.01%38.59M | -21.68%37.86M | -39.26%30.73M | 220.43%50.59M | 157.10%45.58M |
| Current changes in cash | -173.88%-33.99M | 2,800.91%8.86M | -192.54%-6.91M | 229.83%24.27M | -103.13%-28.88M | 11,866.50%46.01M | 82.16%-328K | 432.59%7.47M | -154.51%-18.69M | -143.37%-14.22M |
| Effect of exchange rate changes | -235.89%-621K | -157.33%-602K | 124.78%84K | 205.91%1.24M | 110.83%68K | 187.38%457K | 8,176.92%1.05M | -11,200.00%-339K | -328.38%-1.17M | -838.82%-628K |
| End cash Position | -72.89%23.06M | 49.45%57.67M | 30.49%49.41M | 82.99%56.24M | 82.99%56.24M | 86.61%85.05M | -17.01%38.59M | -21.68%37.86M | -39.26%30.73M | -39.26%30.73M |
| Free cash flow | -197.52%-27.68M | 3.64%-20.03M | -12.99%-26.74M | 3.30%-76.46M | 15.52%-22.71M | 34.79%-9.3M | -4.45%-20.79M | -31.30%-23.66M | -161.35%-79.07M | -142.60%-26.88M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg